TRAWS PHARMA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6444 USD | +0.73% |
|
-0.88% | -13.57% |
| May. 07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 38.59 | 86.15 | 53.27 | 13.51 | 15.66 | 13.49 | - | - |
| Enterprise Value (EV) 1 | 38.59 | 86.15 | 53.27 | 13.51 | 15.66 | 13.49 | 13.49 | 13.49 |
| P/E ratio | -0.26 x | -3.33 x | -2.66 x | -0.71 x | -0.83 x | -0.74 x | -0.77 x | -0.79 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.7 x | 373 x | 236 x | 59.8 x | 69.3 x | 64.2 x | 45 x | 45 x |
| EV / Revenue | 17.7 x | 373 x | 236 x | 59.8 x | 69.3 x | 64.2 x | 45 x | 45 x |
| EV / EBITDA | -1.78 x | -3.45 x | -3.23 x | -0.69 x | -0.77 x | -0.57 x | -0.47 x | -0.41 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 6,718 | 12,330 | 20,891 | 20,926 | 21,003 | 21,086 | - | - |
| Reference price 2 | 5.745 | 6.987 | 2.550 | 0.6457 | 0.7456 | 0.6397 | 0.6397 | 0.6397 |
| Announcement Date | 3/24/20 | 3/11/21 | 3/17/22 | 3/16/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.183 | 0.231 | 0.226 | 0.226 | 0.226 | 0.21 | 0.3 | 0.3 |
| EBITDA 1 | -21.68 | -24.98 | -16.48 | -19.61 | -20.28 | -23.5 | -28.6 | -33.2 |
| EBIT 1 | -21.7 | -24.99 | -16.5 | -19.63 | -20.3 | -23.5 | -28.6 | -33.2 |
| Operating Margin | -994% | -10,819.48% | -7,299.12% | -8,684.51% | -8,981.42% | -11,190.48% | -9,533.33% | -11,066.67% |
| Earnings before Tax (EBT) 1 | -21.49 | -25.15 | -16.16 | -18.96 | -18.95 | -23.3 | -28.4 | -33 |
| Net income 1 | -21.5 | -25.16 | -16.16 | -18.96 | -18.95 | -23.3 | -28.4 | -33 |
| Net margin | -985.02% | -10,890.48% | -7,151.77% | -8,391.15% | -8,384.07% | -11,095.24% | -9,466.67% | -11,000% |
| EPS 2 | -22.35 | -2.100 | -0.9600 | -0.9100 | -0.9000 | -0.8650 | -0.8300 | -0.8100 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/11/21 | 3/17/22 | 3/16/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.056 | 0.056 | 0.057 | 0.057 | 0.056 | 0.056 | 0.057 | 0.057 | 0.056 | 0.056 | 0.06 | 0.06 | 0.06 |
| EBITDA | -3.759 | -4.129 | -4.116 | -5.638 | -5.73 | -6.134 | - | -5.084 | -4.458 | - | - | - | - |
| EBIT | -3.763 | -4.132 | -4.12 | -5.641 | -5.734 | -6.137 | -4.61 | -5.089 | -4.462 | - | - | - | - |
| Operating Margin | -6,719.64% | -7,378.57% | -7,228.07% | -9,896.49% | -10,239.29% | -10,958.93% | -8,087.72% | -8,928.07% | -7,967.86% | - | - | - | - |
| Earnings before Tax (EBT) | -3.764 | -4.122 | -4.024 | -5.398 | -5.42 | -5.775 | -4.25 | -4.739 | -4.184 | - | - | - | - |
| Net income | -3.764 | -4.122 | -4.024 | -5.398 | -5.42 | -5.775 | -4.25 | -4.739 | -4.184 | - | - | - | - |
| Net margin | -6,721.43% | -7,360.71% | -7,059.65% | -9,470.18% | -9,678.57% | -10,312.5% | -7,456.14% | -8,314.04% | -7,471.43% | - | - | - | - |
| EPS 2 | -0.1600 | -0.2000 | -0.1900 | -0.2600 | -0.2600 | -0.2800 | -0.2000 | -0.2300 | -0.2000 | -0.2400 | -0.2500 | -0.2800 | -0.2900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/22 | 5/11/22 | 8/11/22 | 11/14/22 | 3/16/23 | 5/15/23 | 8/10/23 | 11/14/23 | 4/1/24 | 5/15/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/11/21 | 3/17/22 | 3/16/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6397
USD
Average target price
8
USD
Spread / Average Target
+1,150.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.57% | 13.49M | |
| +41.68% | 54.04B | |
| +43.57% | 41.96B | |
| -1.13% | 41.92B | |
| -7.59% | 28.35B | |
| +12.22% | 26.35B | |
| -22.46% | 19B | |
| +7.84% | 13B | |
| +29.16% | 12.28B | |
| +25.14% | 12.19B |
- Stock Market
- Equities
- TRAW Stock
- Financials Traws Pharma, Inc.
